procarbazine has been researched along with Astrocytoma, Grade IV in 80 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the feasibility of 1-(4-amino- 2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) of pre-treated procarbazine for elderly patients with newly diagnosed glioblastomas." | 9.12 | Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma. ( Abe, T; Miyagi, N; Ogo, E; Shigemori, M; Terasaki, M, 2007) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine." | 9.10 | Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S, 2002) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 9.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 9.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 9.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "After surgery, patients aged < or = 70 years, with World Health Organization grade 3 or 4 astrocytoma, were randomized to radiotherapy alone (RT) or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV) given at 6-week intervals to a maximum of 12 courses (procarbazine 100 mg/m2 days 1 to 10, lomustine 100 mg/m2 day 1, and vincristine 1." | 9.09 | Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. ( , 2001) |
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 9.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 9.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas." | 9.08 | A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392). ( Adams, G; Flynn, P; Grunnet, M; Hellman, R; Karp, D; Neuberg, DS; Robins, HI; Wagner, H, 1998) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 9.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme." | 9.07 | Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 8.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 7.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| " The interactions between anticancer drugs such as carmustine (BCNU), vincristine (VCR) and procarbazine (PCB) and calcium channel blockers such as nimodipine and verapamil on cultured cells of glioblastoma from eight patients were therefore tested." | 7.70 | The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme. ( Deliorman, S; Durmaz, R; Erol, K; Işiksoy, S; Tel, E; Uyar, R, 1999) |
| "To determine the efficacy of the combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas after failure of either previous radiotherapy alone or previous radiotherapy plus nitrosourea-based chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 6.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 6.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "To evaluate the feasibility of 1-(4-amino- 2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) of pre-treated procarbazine for elderly patients with newly diagnosed glioblastomas." | 5.12 | Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma. ( Abe, T; Miyagi, N; Ogo, E; Shigemori, M; Terasaki, M, 2007) |
| "The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma." | 5.12 | PCV chemotherapy for recurrent glioblastoma. ( Dichgans, J; Dietz, K; Fischer, J; Herrlinger, U; Schmidt, F; Weller, M, 2006) |
| " The group is now preparing a multi-institutional randomized controlled phase II/III study of chemoradiotherapy using ACNU versus procarbazine and ACNU for astrocytoma grades 3 and 4." | 5.11 | Randomized controlled trial on malignant brain tumors--activities of the Japan Clinical Oncology Group-Brain Tumor Study Group. ( Shibui, S, 2004) |
| "To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine." | 5.10 | Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S, 2002) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 5.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 5.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 5.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 5.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "After surgery, patients aged < or = 70 years, with World Health Organization grade 3 or 4 astrocytoma, were randomized to radiotherapy alone (RT) or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV) given at 6-week intervals to a maximum of 12 courses (procarbazine 100 mg/m2 days 1 to 10, lomustine 100 mg/m2 day 1, and vincristine 1." | 5.09 | Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. ( , 2001) |
| "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas." | 5.08 | A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392). ( Adams, G; Flynn, P; Grunnet, M; Hellman, R; Karp, D; Neuberg, DS; Robins, HI; Wagner, H, 1998) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 5.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 5.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme." | 5.07 | Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 4.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 3.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy." | 3.71 | PCV chemotherapy for recurrent glioblastoma multiforme. ( Groeneveld, GJ; Heimans, JJ; Kappelle, AC; Postma, TJ; Sneeuw, KC; Taphoorn, MJ; van den Bent, MJ; van Groeningen, CJ; Zonnenberg, BA, 2001) |
| " The interactions between anticancer drugs such as carmustine (BCNU), vincristine (VCR) and procarbazine (PCB) and calcium channel blockers such as nimodipine and verapamil on cultured cells of glioblastoma from eight patients were therefore tested." | 3.70 | The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme. ( Deliorman, S; Durmaz, R; Erol, K; Işiksoy, S; Tel, E; Uyar, R, 1999) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "The aim of this study was to examine the range of sensitivity of a panel of short-term cultures derived from different types of malignant childhood brain tumours including medulloblastoma, ependymoma and glioblastoma multiforme to three cytotoxic drugs, lomustine (CCNU), vincristine (VCR) and procarbazine (PCB)." | 3.70 | Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine. ( Darling, JL; Harding, B; Harkness, W; Hayward, R; Lewandowicz, GM; Thomas, DG, 2000) |
| " In glioblastomas (histological grade 4, n = 257) the same chemotherapy was evaluated versus two cycles 4 weeks apart of 160 mg lomustine (CCNU) orally instead of BCNU, combined with vincristine and procarbazine (PCV) versus no chemotherapy." | 3.70 | A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. ( Gundersen, S; Lote, K; Watne, K, 1998) |
| "To determine the efficacy of the combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas after failure of either previous radiotherapy alone or previous radiotherapy plus nitrosourea-based chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 2.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 2.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "Estimated 4-year survival for the anaplastic astrocytoma (AA) stratum (n = 116) is 46%." | 2.68 | Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. ( Davis, RL; Gutin, PH; Lamborn, K; Levin, VA; Phillips, TL; Prados, MR; Wara, WM; Wilson, CB, 1995) |
| "Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine." | 2.67 | Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. ( Hager, B; Hannisdal, E; Hirschberg, H; Nome, O; Watne, K, 1992) |
| "Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months." | 2.67 | External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| "Procarbazine was not given as a specified protocol, but for patients who were ineligible or refused other protocols." | 2.38 | Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. ( Levin, VA; Prados, M; Rodriguez, LA; Silver, P, 1989) |
| "In the present study, patients with anaplastic astrocytoma treated with chemotherapy protocols other than TMZ had the longest OS; however, in the glioblastoma group, OS was 32 months in those treated with standard TMZ and 12 months in those treated with other protocols (P = 0." | 1.43 | High-grade glioma in children and adolescents: a single-center experience. ( Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F, 2016) |
| "Six patients (1 anaplastic astrocytoma) have developed progressive disease." | 1.28 | VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors. ( Calogero, JA; Hellman, RM; Kaplan, BM, 1990) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| "Seven human brain tumors were transplanted into the brains (6/7 takes) and subcutaneous tissues (7/7 takes) of athymic nude mice." | 1.26 | Human brain tumor transplantation into nude mice. ( Basler, GA; Chernik, NL; Posner, JB; Shapiro, WR, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (23.75) | 18.7374 |
| 1990's | 28 (35.00) | 18.2507 |
| 2000's | 24 (30.00) | 29.6817 |
| 2010's | 9 (11.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Carvalho, BF | 1 |
| Fernandes, AC | 1 |
| Almeida, DS | 1 |
| Sampaio, LV | 1 |
| Costa, A | 1 |
| Caeiro, C | 1 |
| Osório, L | 1 |
| Castro, L | 1 |
| Linhares, P | 1 |
| Damasceno, M | 1 |
| Vaz, RC | 1 |
| Yazici, G | 1 |
| Zorlu, F | 1 |
| Cengiz, M | 1 |
| Ozyigit, G | 1 |
| Eren, G | 1 |
| Yüce, D | 1 |
| Varan, A | 1 |
| Akyuz, C | 1 |
| Akalan, N | 1 |
| Gurkaynak, M | 1 |
| Khasraw, M | 1 |
| Lee, A | 1 |
| McCowatt, S | 1 |
| Kerestes, Z | 1 |
| Buyse, ME | 1 |
| Back, M | 1 |
| Kichenadasse, G | 1 |
| Ackland, S | 1 |
| Wheeler, H | 1 |
| Ashley, DM | 1 |
| Riffkin, CD | 1 |
| Lovric, MM | 1 |
| Mikeska, T | 1 |
| Dobrovic, A | 1 |
| Maxwell, JA | 1 |
| Friedman, HS | 1 |
| Drummond, KJ | 1 |
| Kaye, AH | 1 |
| Gan, HK | 1 |
| Johns, TG | 1 |
| Hawkins, CJ | 1 |
| Nakamura, M | 1 |
| Shimada, K | 1 |
| Nakase, H | 1 |
| Konishi, N | 1 |
| Hamasaki, K | 1 |
| Nakamura, H | 3 |
| Ueda, Y | 1 |
| Makino, K | 1 |
| Kuratsu, J | 2 |
| Ogawa, K | 2 |
| Ishiuchi, S | 1 |
| Inoue, O | 2 |
| Yoshii, Y | 2 |
| Saito, A | 2 |
| Watanabe, T | 1 |
| Iraha, S | 1 |
| Toita, T | 2 |
| Kakinohana, Y | 2 |
| Ariga, T | 1 |
| Kasuya, G | 1 |
| Murayama, S | 2 |
| Kuhnhenn, J | 1 |
| Kowalski, T | 1 |
| Steenken, S | 1 |
| Ostermann, K | 1 |
| Schlegel, U | 1 |
| Shibui, S | 2 |
| Narita, Y | 1 |
| Mizusawa, J | 1 |
| Beppu, T | 1 |
| Ogasawara, K | 1 |
| Sawamura, Y | 1 |
| Kobayashi, H | 1 |
| Nishikawa, R | 1 |
| Mishima, K | 1 |
| Muragaki, Y | 1 |
| Maruyama, T | 1 |
| Kochi, M | 1 |
| Minamida, Y | 1 |
| Yamaki, T | 1 |
| Kumabe, T | 1 |
| Tominaga, T | 1 |
| Kayama, T | 1 |
| Sakurada, K | 1 |
| Nagane, M | 1 |
| Kobayashi, K | 1 |
| Ito, T | 1 |
| Yazaki, T | 1 |
| Sasaki, H | 1 |
| Tanaka, K | 1 |
| Takahashi, H | 1 |
| Asai, A | 1 |
| Todo, T | 1 |
| Wakabayashi, T | 1 |
| Takahashi, J | 1 |
| Takano, S | 1 |
| Fujimaki, T | 1 |
| Sumi, M | 1 |
| Miyakita, Y | 1 |
| Nakazato, Y | 1 |
| Sato, A | 1 |
| Fukuda, H | 1 |
| Nomura, K | 1 |
| Afra, D | 1 |
| Sipos, L | 1 |
| Vitanovics, D | 1 |
| Murphy, C | 1 |
| Pickles, T | 1 |
| Knowling, M | 1 |
| Thiesse, B | 1 |
| Brandes, AA | 4 |
| Ermani, M | 4 |
| Basso, U | 3 |
| Paris, MK | 1 |
| Lumachi, F | 1 |
| Berti, F | 3 |
| Amistà, P | 3 |
| Gardiman, M | 2 |
| Iuzzolino, P | 2 |
| Turazzi, S | 3 |
| Monfardini, S | 2 |
| Vastola, F | 1 |
| Pinna, G | 2 |
| Rotilio, A | 2 |
| Scienza, R | 2 |
| Vos, MJ | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 3 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 3 |
| Adachi, G | 1 |
| Ishikawa, Y | 1 |
| Kin, S | 1 |
| Newlands, ES | 1 |
| Foster, T | 1 |
| Zaknoen, S | 2 |
| Liau, CT | 1 |
| Wei, KC | 1 |
| Tseng, CK | 1 |
| Jung, SM | 1 |
| Macdonald, DR | 1 |
| Kiebert, G | 1 |
| Prados, M | 3 |
| Yung, A | 1 |
| Olson, J | 2 |
| Schmidt, F | 1 |
| Fischer, J | 1 |
| Herrlinger, U | 1 |
| Dietz, K | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Terasaki, M | 1 |
| Abe, T | 1 |
| Miyagi, N | 1 |
| Ogo, E | 1 |
| Shigemori, M | 1 |
| Silvani, A | 3 |
| Lamperti, E | 1 |
| Gaviani, P | 1 |
| Eoli, M | 2 |
| Fiumani, A | 1 |
| Salmaggi, A | 2 |
| Falcone, C | 1 |
| Filippini, G | 1 |
| Botturi, A | 1 |
| Boiardi, A | 4 |
| Eyre, HJ | 2 |
| Quagliana, JM | 1 |
| Eltringham, JR | 2 |
| Frank, J | 1 |
| O'Bryan, RM | 1 |
| McDonald, B | 1 |
| Rivkin, SE | 1 |
| Kelly, KA | 1 |
| Kirkwood, JM | 1 |
| Kapp, DS | 1 |
| Lieberman, AN | 1 |
| Foo, SH | 1 |
| Ransohoff, J | 1 |
| Wise, A | 1 |
| George, A | 1 |
| Gordon, W | 1 |
| Walker, R | 1 |
| Morgan, D | 1 |
| Freshney, RI | 1 |
| Darling, JL | 2 |
| Thomas, DG | 2 |
| Celik, F | 1 |
| West, CR | 2 |
| Avellanosa, AM | 2 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Rana, SR | 1 |
| Haddy, TB | 1 |
| Ashayeri, E | 1 |
| Goldson, AL | 1 |
| Levin, VA | 15 |
| Maor, MH | 2 |
| Thall, PF | 1 |
| Yung, WK | 6 |
| Bruner, J | 3 |
| Sawaya, R | 1 |
| Kyritsis, AP | 5 |
| Leeds, N | 1 |
| Woo, S | 1 |
| Rodriguez, L | 1 |
| Loeffler, JS | 1 |
| Shrieve, DC | 1 |
| Coleman, CN | 1 |
| Sobol, RE | 1 |
| Fakhrai, H | 1 |
| Shawler, D | 1 |
| Gjerset, R | 1 |
| Dorigo, O | 1 |
| Carson, C | 1 |
| Khaleghi, T | 1 |
| Koziol, J | 1 |
| Shiftan, TA | 1 |
| Royston, I | 1 |
| Prados, MR | 1 |
| Wara, WM | 6 |
| Davis, RL | 4 |
| Gutin, PH | 6 |
| Phillips, TL | 4 |
| Lamborn, K | 1 |
| Wilson, CB | 7 |
| Jeremic, B | 4 |
| Grujicic, D | 2 |
| Antunovic, V | 2 |
| Djuric, L | 3 |
| Stojanovic, M | 2 |
| Shibamoto, Y | 2 |
| Jaeckle, KA | 4 |
| Gleason, MJ | 2 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Hildebrand, J | 1 |
| De Witte, O | 1 |
| Sahmoud, T | 1 |
| Hellman, R | 1 |
| Neuberg, DS | 1 |
| Wagner, H | 1 |
| Grunnet, M | 1 |
| Robins, HI | 1 |
| Karp, D | 1 |
| Flynn, P | 1 |
| Adams, G | 1 |
| van Groeningen, CJ | 2 |
| Witjes, RJ | 1 |
| Weerts, JG | 1 |
| Kralendonk, JH | 1 |
| Bauman, GS | 1 |
| Fisher, BJ | 1 |
| Cairncross, JG | 1 |
| Macdonald, D | 1 |
| Gundersen, S | 1 |
| Lote, K | 1 |
| Watne, K | 2 |
| Scelzi, E | 1 |
| Licata, C | 1 |
| Fiorentino, MV | 1 |
| Groves, MD | 1 |
| Meyers, C | 1 |
| Sawaya, RE | 1 |
| Hess, K | 1 |
| Bruner, JM | 2 |
| Peterson, P | 1 |
| Durmaz, R | 1 |
| Deliorman, S | 1 |
| Uyar, R | 1 |
| Işiksoy, S | 1 |
| Erol, K | 1 |
| Tel, E | 1 |
| Osoba, D | 2 |
| Brada, M | 2 |
| Pozzi, A | 1 |
| Broggi, G | 2 |
| Albright, RE | 1 |
| Fredericks, R | 1 |
| Fink, K | 1 |
| Prados, MD | 6 |
| Spence, A | 1 |
| Hohl, RJ | 1 |
| Shapiro, W | 1 |
| Glantz, M | 1 |
| Greenberg, H | 1 |
| Selker, RG | 1 |
| Vick, NA | 1 |
| Rampling, R | 1 |
| Friedman, H | 1 |
| Phillips, P | 1 |
| Yue, N | 1 |
| Lewandowicz, GM | 1 |
| Harding, B | 1 |
| Harkness, W | 1 |
| Hayward, R | 1 |
| Uhm, JH | 1 |
| Choucair, A | 1 |
| Flynn, PJ | 1 |
| Chang, SM | 1 |
| Hess, KR | 2 |
| Kappelle, AC | 1 |
| Taphoorn, MJ | 1 |
| Groeneveld, GJ | 1 |
| van den Bent, MJ | 1 |
| Zonnenberg, BA | 1 |
| Sneeuw, KC | 1 |
| Wong, ET | 1 |
| Croteau, D | 1 |
| Mikkelsen, T | 1 |
| Pasetto, LM | 1 |
| Guglielmi, B | 1 |
| Volpin, L | 1 |
| Crafts, DC | 1 |
| Schultz, MJ | 1 |
| Boldrey, EB | 3 |
| Enot, KJ | 2 |
| Pischer, TL | 2 |
| Seager, M | 1 |
| Elashoff, RM | 1 |
| Ertel, IJ | 2 |
| Boesel, C | 1 |
| Shapiro, WR | 1 |
| Basler, GA | 1 |
| Chernik, NL | 1 |
| Posner, JB | 1 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Tsukada, Y | 1 |
| Higby, DJ | 1 |
| Bakshi, S | 1 |
| Reese, PA | 1 |
| Jennings, E | 1 |
| Hannisdal, E | 1 |
| Nome, O | 1 |
| Hager, B | 1 |
| Hirschberg, H | 1 |
| Milanesi, I | 1 |
| Fariselli, L | 1 |
| Jovanovic, D | 1 |
| Djuric, LJ | 1 |
| Jevremovic, S | 1 |
| Mijatovic, LJ | 1 |
| Sneed, PK | 2 |
| Weaver, KA | 2 |
| Larson, DA | 2 |
| Leibel, SA | 1 |
| Silver, P | 3 |
| Ahn, DK | 1 |
| Flam, MS | 1 |
| Hannigan, J | 1 |
| Barjaktarević, Z | 1 |
| Mijatović, L | 1 |
| Hellman, RM | 1 |
| Calogero, JA | 1 |
| Kaplan, BM | 1 |
| Newton, HB | 1 |
| Junck, L | 1 |
| Bromberg, J | 1 |
| Page, MA | 1 |
| Greenberg, HS | 1 |
| Sposto, R | 1 |
| Jenkin, RD | 1 |
| Boesel, CP | 1 |
| Venes, JL | 1 |
| Ortega, JA | 1 |
| Evans, AE | 1 |
| Wara, W | 1 |
| Hammond, D | 1 |
| Rodriguez, LA | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Vestnys, P | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Gehan, EA | 1 |
| Vogel, FS | 1 |
| Al-Sarraf, M | 1 |
| Talley, RW | 1 |
| Costanzi, JJ | 1 |
| Athens, JW | 1 |
| Oishi, N | 1 |
| Fletcher, WS | 1 |
| Pendergrass, TW | 1 |
| Milstein, JM | 1 |
| Geyer, JR | 1 |
| Mulne, AF | 1 |
| Kosnik, EJ | 1 |
| Morris, JD | 1 |
| Heideman, RL | 1 |
| Ruymann, FB | 1 |
| Stuntz, JT | 1 |
| Bleyer, WA | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Vasantha Kumar, AR | 1 |
| Renaudin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx[NCT03843671] | Phase 2 | 400 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for procarbazine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
Glioblastoma multiforme: pathology, natural history and treatment.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Astrocytoma; Brain Neoplasms; Carmus | 1984 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Female; Glioblastoma; Glioma; Hum | 1989 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
36 trials available for procarbazine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine | 2016 |
Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain N | 2012 |
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradi | 2013 |
[Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali | 2002 |
Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Daca | 2002 |
A prospective study on glioblastoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mod | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Randomized controlled trial on malignant brain tumors--activities of the Japan Clinical Oncology Group-Brain Tumor Study Group.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans | 2004 |
PCV chemotherapy for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; D | 2006 |
Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Brain Neoplasm | 2007 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report.
Topics: Brain Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Female; Glioblastoma; Humans; | 1983 |
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 1995 |
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1995 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Comb | 1998 |
Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain; Brain N | 1999 |
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain | 1999 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2000 |
Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Central Nervous System Neo | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 2002 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Glioblastoma; Huma | 1992 |
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1992 |
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Combine | 1991 |
Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bro | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glio | 1986 |
38 other studies available for procarbazine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Comparative efficacy of bevacizumab and PCV chemotherapy in recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; | 2015 |
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2015 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
Radiation-induced glioblastoma occurring 35 years after radiation therapy for medulloblastoma: case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Glioblastoma; Humans; M | 2010 |
Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Glio | 2003 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
Long term survival among patients with malignant brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Humans; M | 1982 |
Assay of anticancer drugs in tissue culture: cell cultures of biopsies from human astrocytoma.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Glioblastoma; Humans; | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Intraoperative radiotherapy in childhood malignant astrocytoma.
Topics: Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioblastoma; Humans; Intraoperative | 1984 |
Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant | 1995 |
Interleukin-2 gene therapy in a patient with glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Combined Modality | 1995 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Duke researchers link brain tumor drug resistance to mismatch repair deficiency.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resista | 1997 |
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1998 |
Bihemispheric malignant glioma: one size does not fit all.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome; Glioblastoma; | 1998 |
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
Topics: Administration, Oral; Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Brain | 1998 |
The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Bloc | 1999 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child; Dose-Response Relationship, Drug; | 2000 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Glioblasto | 2001 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Female; Gliobl | 2001 |
Brain tumors in children.
Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female; | 1978 |
Human brain tumor transplantation into nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Transplantati | 1979 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Chemotherapy of nonirradiated malignant gliomas. Phase II: study of the combination of methyl-CCNU, vincristine, and procarbazine.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Brain Neoplasms; Drug Evaluation; Drug Therapy, Com | 1979 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
Acute toxicity from BOPP (BCNU, vincristine, procarbazine, cisplatinum) chemotherapy for glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Glioblastoma; Humans; Procarb | 1990 |
VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Etoposide; Female; Glioblastom | 1990 |
Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Drug Eval | 1990 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb | 1987 |
Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study.
Topics: Adolescent; Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Electroencephalography; Epe | 1974 |